Cortechs.ai | Cortechs.ai Announces Strategic Distribution Partnership with Medical Horizons to Expand Presence in Italy, Turkey, and the Middle East

Cortechs.ai Announces Strategic Distribution Partnership with Medical Horizons to Expand Presence in Italy, Turkey, and the Middle East

San Diego, CA – Cortechs.ai, a leader in AI-powered medical imaging solutions, is pleased to announce a strategic distribution partnership with Medical Horizons, a premier AI-powered medical device distributor based in Florence, Italy. This partnership will expand the reach of Cortechs.ai’s innovative products across Italy, Turkey, and the Middle East, bringing advanced AI-driven imaging solutions to healthcare professionals and institutions in these key markets.

Medical Horizons has established itself as a trusted distributor of cutting-edge medical technologies, working closely with top-tier companies worldwide to integrate high-level AI solutions into clinical practice. The company’s extensive sales network and expertise in cloud-based healthcare solutions will provide a strong foundation for accelerating the adoption of Cortechs.ai’s technology among neurologists, radiologists, and other healthcare professionals.

“We are incredibly excited to partner with Medical Horizons as we expand our global footprint,” said Kyle Frye, CEO of Cortechs.ai. “Their deep industry knowledge, extensive relationships with key healthcare providers, and commitment to innovation make them the ideal partner to introduce our AI-powered imaging solutions to new markets. This collaboration marks a significant milestone in our global expansion strategy and underscores our commitment to enhancing clinical decision-making through advanced AI technology.”

Medical Horizons has a proven track record of successfully bringing sophisticated AI-based medical solutions to leading healthcare institutions, including installations at renowned centers such as Campus Biomedico Roma, Meyer Labs Florence, Sant’ Andrea Roma, and Gruppo Multimedia Milano.

“Medical Horizons is the key to unlocking the full potential of Cortechs.ai Italy, Turkey, and the Middle East,” said Daniel D’Amour, Director of Global Partnerships at Cortechs.ai. “Their deep market expertise, strong customer relationships, and dedication to innovation align perfectly with our mission to advance AI-driven imaging solutions. We are truly grateful for this partnership and excited to work together to expand access to our technology, improving patient care across these regions.”

The partnership between Cortechs.ai and Medical Horizons comes at a time of growing demand for AI-powered diagnostic tools. By combining Cortechs.ai’s industry-leading innovations with Medical Horizons’ extensive market reach, the two companies are poised to make a lasting impact on the global healthcare landscape.

“This partnership marks a significant advancement in meeting the growing demand for AI-driven support in radiology and neurology,” said Rolando Arpi, Product Manager, Medical Horizons. “The introduction of Cortechs.ai’s proven solutions to the European market will not only strengthen our existing relationships but also attract new healthcare providers seeking cutting-edge AI technologies. We anticipate strong adoption and rapid expansion as clinicians recognize the value of these innovations in improving patient care.”

For more information about Cortechs.ai and Medical Horizons, visit https://www.cortechs.ai/ and https://www.medicalhorizons.it/.

 

About Cortechs.ai

Cortechs.ai is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical device software that quantifies and tracks neurodegeneration and prostate cancer, helping clinicians detect and monitor clinically significant cases. Cortechs.ai’s industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess prostate health, including detection and monitoring of cancer. The company also has FDA-cleared products for use in assessing neurological disorders such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit www.cortechs.ai and follow us on Twitter, LinkedIn, and Facebook.

 

For more information, please contact:

___________

info@cortechs.ai

+1 858 459 9700

More Resources

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.

09/16/2025

OnQ Prostate for Focal Therapy

Read how OnQ Prostate supports focal therapy by personalizing prostate cancer care for patients while minimizing the risks associated with it.

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage
Scroll to Top